Janney Capital analyst Ken Trbovich raised his estimates for GW Pharmaceuticals and increased his fair value estimate for the shares to $55, citing the "excitement" he heard among physicians who regularly treat patients with Epidiolex during the Annual Epilepsy Society meeting last December. However, he continues to think regulatory and commercial challenges will likely prevent Epidiolex from achieving high expectations set by the market, even if the drug is approved on first review for Dravet Syndrome and LGS and the subsequent studies in infantile spasm and tuberous sclerosis succeed. Trbovich, who notes that consensus estimates call for Epidiolex to hit $900M in sales in just 3-4 years even though the most recent FDA-approved drugs for orphan epilepsy indications had sales in the range of $100M-$300M 4-8 years after launch, keeps a Sell rating on GW shares.